Ascendis Pharma Presents TransCon PTH Phase 3 52-week Skeletal Dynamics Data At ASBMR 2023
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma has presented 52-week results from the Phase 3 PaTHway Trial at ASBMR 2023. The results showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms. Bone turnover markers trended toward the normal reference ranges for sex and menopausal status and corresponded to smaller changes in bone mineral density (BMD) through Week 52.
October 16, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's Phase 3 PaTHway Trial results show positive trends in patients treated with TransCon PTH, which could potentially boost the company's reputation and stock value.
The positive results from the Phase 3 PaTHway Trial indicate that Ascendis Pharma's TransCon PTH is effective in treating chronic hypoparathyroidism. This could potentially lead to increased demand for the drug, boosting the company's revenues and stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100